Available and future treatments for atypical parkinsonism. A systematic review

source extracted confidence: high 2026-04-09
#adult #aged #antiparkinson-agents #child #humans

Available and future treatments for atypical parkinsonism. A systematic review

Moretti et al., 2019 | CNS Neurosci Ther | Systematic Review

Citation

Moretti Davide Vito. Available and future treatments for atypical parkinsonism. A systematic review. CNS Neurosci Ther. 2019-Feb;25(2):159-174. doi:10.1111/cns.13068

Abstract

AIMS: Success in treating patients with atypical parkinsonian syndromes, namely progressive supranuclear palsy (PSP), cortico-basal degeneration (CBD), multiple system atrophy (MSA), Parkinson's disease with dementia (PDD), and Lewy body dementia with (LBD), remains exceedingly low. The present work overviews the most influential research literature collected on MEDLINE, ISI Web of Science, Cochrane Library, and Scopus for available treatment in atypical parkinsonisms without time restriction. DISCUSSION: Transdermal rotigotine, autologous mesenchymal stem cells, tideglusib, and coenzyme Q10 along with donepezil, rivastigmine, memantine, and the deep brain stimulation have shown some benefits in alleviating symptoms in APS. Moreover, many new clinical trials are ongoing testing microtubule stabilizer, antitau monoclonal antibody, tau acetylation inhibition, cell replacement, selective serotonin reuptake inhibitor, active immunization, inhibition of toxic α-synuclein oligomers formation, and inhibition of microglia. CONCLUSION: A detailed knowledge of the pathological mechanism underlying the disorders is needed, and disease-modifying therapies are required to offer better therapeutic options to physician and caregivers of APS patients.

Key Findings

A detailed knowledge of the pathological mechanism underlying the disorders is needed, and disease-modifying therapies are required to offer better therapeutic options to physician and caregivers of APS patients.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population atypical parkinsonian syndromes
Sample Size See abstract
Age Range See abstract
Condition See abstract

MeSH Terms

  • Adult
  • Aged
  • Antiparkinson Agents
  • Child
  • Humans
  • Parkinsonian Disorders

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Journal Article, Systematic Review
  • Vertical: coq10

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09